Table 2.xls (17.5 kB)
IRs of intracranial, gastrointestinal, urogenital and other bleeding leading to hospitalization associated with first use of rivaroxaban in subgroups of specific interest.
dataset
posted on 2024-03-07, 18:34 authored by Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M. C. Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García RodríguezIRs of intracranial, gastrointestinal, urogenital and other bleeding leading to hospitalization associated with first use of rivaroxaban in subgroups of specific interest.
History
Usage metrics
Categories
Keywords
vitamin k antagonistsvitamin k antagonistroutine clinical practicerecent cancer history9 &# 8211time users treatedbleeding ), deatheuropean rivaroxaban post44 737 rivaroxabanxlink "> overallxlink "> cohortsamong rivaroxaban userscrude incidence ratesdecember 2017 ).venous thromboembolism indicationxlink ">rivaroxaban usersvenous thromboembolismincidence ratesdecember 2017vte indicationdecember 2018december 2016december 2011study providesstudy endsecondary preventionsafety profilesafety outcomerenal impairmentjanuary 2012gastrointestinal bleedingcomplement findingsatrial fibrillation
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC